Stay updated on IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.

Latest updates to the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedSystem revision history updated to add v3.5.0 and remove v3.4.3.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed from the history.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page history shows a new revision (v3.4.2) replacing the previous revision (v3.4.1). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedThe history now shows a new revision entry (v3.4.1) added to the record, and the previous revision (v3.4.0) has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page history shows a new revision label from v3.3.3 to v3.3.4, which is a minor backend update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check101 days agoChange DetectedAdded a footer notice 'Revision: v3.3.3'. Removed the 'HHS Vulnerability Disclosure' link and the 'Revision: v3.3.2' reference.SummaryDifference0.1%

Stay in the know with updates to IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IcoSema vs. Glargine-Aspart in Type 2 Diabetes Clinical Trial page.